Oncogenic drivers dictate immune control of acute myeloid leukemia

Rebecca J. Austin, Jasmin Straube, Rohit Halder, Yashaswini Janardhanan, Claudia Bruedigam, Matthew Witkowski, Leanne Cooper, Amy Porter, Matthias Braun, Fernando Souza-Fonseca-Guimaraes, Simone A. Minnie, Emily Cooper, Sebastien Jacquelin, Axia Song, Tobias Bald, Kyohei Nakamura, Geoffrey R. Hill, Iannis Aifantis, Steven W. Lane () and Megan J. Bywater ()
Additional contact information
Rebecca J. Austin: QIMR Berghofer Medical Research Institute
Jasmin Straube: QIMR Berghofer Medical Research Institute
Rohit Halder: QIMR Berghofer Medical Research Institute
Yashaswini Janardhanan: QIMR Berghofer Medical Research Institute
Claudia Bruedigam: QIMR Berghofer Medical Research Institute
Matthew Witkowski: NYU Grossman School of Medicine
Leanne Cooper: QIMR Berghofer Medical Research Institute
Amy Porter: QIMR Berghofer Medical Research Institute
Matthias Braun: QIMR Berghofer Medical Research Institute
Fernando Souza-Fonseca-Guimaraes: The University of Queensland
Simone A. Minnie: QIMR Berghofer Medical Research Institute
Emily Cooper: QIMR Berghofer Medical Research Institute
Sebastien Jacquelin: QIMR Berghofer Medical Research Institute
Axia Song: QIMR Berghofer Medical Research Institute
Tobias Bald: QIMR Berghofer Medical Research Institute
Kyohei Nakamura: QIMR Berghofer Medical Research Institute
Geoffrey R. Hill: QIMR Berghofer Medical Research Institute
Iannis Aifantis: NYU Grossman School of Medicine
Steven W. Lane: QIMR Berghofer Medical Research Institute
Megan J. Bywater: QIMR Berghofer Medical Research Institute

Nature Communications, 2023, vol. 14, issue 1, 1-14

Abstract: Abstract Acute myeloid leukemia (AML) is a genetically heterogeneous, aggressive hematological malignancy induced by distinct oncogenic driver mutations. The effect of specific AML oncogenes on immune activation or suppression is unclear. Here, we examine immune responses in genetically distinct models of AML and demonstrate that specific AML oncogenes dictate immunogenicity, the quality of immune response and immune escape through immunoediting. Specifically, expression of NrasG12D alone is sufficient to drive a potent anti-leukemia response through increased MHC Class II expression that can be overcome with increased expression of Myc. These data have important implications for the design and implementation of personalized immunotherapies for patients with AML.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-37592-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37592-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-37592-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().